Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUC1 Vaccine for Immune Interception in DCIS
NCT06218303Phase 1Recruiting
- Start
- Feb 2024
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of muc1 peptide vaccine in ductal carcinoma in situ (DCIS) (2 arms). Primary endpoint: Immunogenicity of MUC1 vaccine at 12 weeks. Started Feb 2024; status: recruiting.
02
Drugs
muc1 peptide vaccine
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT06218303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218303.